NEXALIN TECHNOLOGY INC. news, videos and press releases
For more news please use our advanced search feature.
NEXALIN TECHNOLOGY INC. - More news...
NEXALIN TECHNOLOGY INC. - More news...
- Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
- New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
- Nexalin Technology CEO Provides Letter to Shareholders
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
- Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
- Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
- Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
- New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
- Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
- Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
- Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
- Nexalin Technology Announces Closing of $5.2 Million Public Offering
- Nexalin Technology Announces Pricing of $5.2 Million Public Offering
- Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
- Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
- Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
- Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
- FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
- Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
- Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
- Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
- Nexalin Technology CEO Provides Letter to Shareholders
- Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
- Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
- Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
- Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
- Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
- Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
- Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
- Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
